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HOXA10 is necessary for embryonic patterning of skeletal elements, but its function in bone formation
beyond this early developmental stage is unknown. Here we show that HOXA10 contributes to osteogenic
lineage determination through activation of Runx2 and directly regulates osteoblastic phenotypic genes. In
response to bone morphogenic protein BMP2, Hoxa10 is rapidly induced and functions to activate the Runx2
transcription factor essential for bone formation. A functional element with the Hox core motif was charac-
terized for the bone-related Runx2 P1 promoter. HOXA10 also activates other osteogenic genes, including the
alkaline phosphatase, osteocalcin, and bone sialoprotein genes, and temporally associates with these target
gene promoters during stages of osteoblast differentiation prior to the recruitment of RUNX2. Exogenous
expression and small interfering RNA knockdown studies establish that HOXA10 mediates chromatin hyper-
acetylation and trimethyl histone K4 (H3K4) methylation of these genes, correlating to active transcription.
HOXA10 therefore contributes to early expression of osteogenic genes through chromatin remodeling. Impor-
tantly, HOXA10 can induce osteoblast genes in Runx2 null cells, providing evidence for a direct role in
mediating osteoblast differentiation independent of RUNX2. We propose that HOXA10 activates RUNX2 in
mesenchymal cells, contributing to the onset of osteogenesis, and that HOXA10 subsequently supports bone
formation by direct regulation of osteoblast phenotypic genes.
Patterning and development of the skeleton are complex
processes involving signaling proteins and transcription factors
that function as determinants for bone formation. Among the
principal regulatory cascades for the development of the skel-
eton are Hox genes that determine the position and shape of a
tissue element (19, 54) and the bone morphogenetic proteins
(BMPs), which induce the differentiation of mesenchymal cells
to osteoblast and chondroblast lineages (18, 84). BMP2 signal-
ing leads to the induction of a number of transcription factors,
including RUNX2 (28) and OSTERIX (42, 56), which are
essential for bone development (34, 45, 69). Several HOX and
homeodomain proteins have been identified as molecular tar-
gets of BMP-mediated gene transcription during early stages
of bone formation by microarray gene expression profiling
studies (3, 33). The present study was aimed at characterizing
a BMP2-inducible gene, the Homeobox a10 (HOXA10) gene,
as a candidate for contributing to commitment and develop-
ment of the osteoblast phenotype.
Mammalian Hox genes (homologues of the Drosophila ho-
meotic genes) encode transcription factors crucial in regional
development along the anterior-posterior axis during embryo-
genesis (44, 64). The mouse and human genomes contain 39
Hox genes, which are grouped into four clusters, Hoxa, Hoxb,
Hoxc, and Hoxd, positioned on four separate chromosomes in
13 paralogs (38, 44). Hoxa10 is a member of the Abdominal B
(Abd B) class of homeobox protein-encoding genes, represent-
ing the most 5 genes in the cluster consisting of paralog genes
from Hoxa 9 to Hoxa 13 (4, 44, 50). The corresponding class of
homeobox proteins binds preferentially to a consensus core of
TTAT or TTAC, which is distinct from the TAAT homeodo-
main consensus core binding site recognized by MSX and DLX
proteins (4). HOXA10 DNA binding is influenced by flanking
sequences and the formation of complexes with HOXA10-
interacting proteins of the MEIS and PBX classes of transcrip-
tion factors, as well as other coregulatory proteins, such as
histone deacetylase 2 (13, 51, 60, 72, 74, 81).
Several of the Hox genes are essential for normal skeletal
development (31, 64). The nonparalogous Hoxa10 and Hoxd11
genes cooperate in the development of the forelimbs and axial
skeleton and are required to globally pattern the mammalian
skeleton (6, 7, 26, 68, 80). Inactivation of the paralogous
Hoxa10 and Hoxd10 genes results in alterations in the forma-
tion of the forelimbs and hind limbs. Hoxa10/ mice revealed
an active role for the gene in modeling the femur, tibia, and
fibula (12, 79). Transgenic expression of HOXA10 in pre-
somitic mesoderm of the mouse resulted in vertebrae without
ribs (11). HOXA10 is expressed in the presomitic mesoderm,
which develops into the axial skeleton and cooperates with
other Hox genes (e.g., Hoxd11) for normal skeletal develop-
ment (11, 26, 31, 64). Despite the considerable genetic evi-
dence that HOXA10 has critical skeletal functions, target
genes of HOXA10 in bone have not been identified.
In this study we have characterized HOXA10 regulation of
the key osteogenic factor Runx2, as well as RUNX2 target
genes, identifying Hoxa10-specific regulatory elements in pro-
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moters of the Runx2, osteocalcin (OC), alkaline phosphatase,
and bone sialoprotein osteoblast-related genes. This discovery
of a Hox regulatory factor in activating Runx2 provides novel
insights for a mechanism that regulates a transcription factor
essential for bone formation (43, 58). Although Runx2 is rap-
idly induced in response to BMP2 and present in developing
limbs, somites, and mesenchymal condensations prior to chon-
drogenic and osteoblast differentiation (23, 46, 76), a Smad-
responsive element has not been defined. Thus, BMP2-in-
duced HOXA10 represents a key regulator of Runx2
transcription during embryogenesis. Our studies also show that
HOXA10 can regulate osteoblast genes independent of
RUNX2. We have thus identified an additional role for
HOXA10 in postnatal bone formation and maintenance of the
osteoblast phenotype. We propose that HOXA10 functions in
two capacities: as a component of a BMP2 signaling cascade
prior to RUNX2 to mediate the developmental induction of
osteogenesis and during osteoblast differentiation to regulate
the temporal expression of bone phenotypic genes to drive
osteoblast maturation through mechanisms involving chroma-
tin remodeling of gene promoters.
(Brian Weiner’s contribution to this paper is in fulfillment of a
Worcester Polytechnic Institute undergraduate thesis project.)
MATERIALS AND METHODS
Cell cultures. C3H10T1/2 and NIH 3T3 cells were maintained in Dulbecco’s
minimal essential medium (MEM) (GIBCO) supplemented with 10% fetal bo-
vine serum (FBS) (Atlanta Biologicals, Georgia). C3H10T1/2 cells were induced
to osteogenesis by BMP2 (300 ng/ml). MC3T3 cells were maintained in -MEM
supplemented with 10% FBS. Primary rat osteoblast cells were isolated from
calvaria according to the procedures described previously (34). The rat osteo-
sarcoma cell line ROS 17/2.8, representing a mature osteoblast phenotype, was
maintained in F-12 medium supplemented with 5% FBS (70). Cells were cul-
tured under osteogenic conditions with MEM (GIBCO-BRL) supplemented
with 10% FBS, 50 g of ascorbic acid/ml, and 10 mM -glycerol phosphate. Bone
marrow stromal cells were isolated from 8-week-old C57BL6 mice and cultured
in MEM containing 10% FBS (29).
Runx2 null cells were isolated from calvarial tissues of mouse embryos (17.5
days postcoitum) of the Runx2 null mouse and immortalized using mouse telom-
erase (TERT). Characterization of this cell line has been described previously
(1). The BMP2 used in these studies was a kind gift from John Wozney (Wyeth
Research, Women’s Health and Musculoskeletal Biology).
Transfection and reporter assays. The Hoxa10 expression clone containing the
mouse cDNA (1.2 kb) of the Hoxa10-1 variant (55 kDa) containing the transac-
tivation domain was kindly provided by Richard L. Maas (Harvard Medical
School, Boston, MA) (4). Transient transfections were performed in six-well
plates at 50 to 70% confluence with 5 l of FuGENE6 transfection reagent with
wild-type (WT) and deleted promoter reporter DNA according to the manufac-
turer’s instructions (Roche, Indianapolis, IN). A tagged Hoxa10 expression vec-
tor (pcDNA3.1-Xpress-Hoxa10) was constructed was used along with a Runx2
expression vector (pcDNA3.1-HA-Runx2) (85) in this study. For control of ex-
pression, vector pcDNA3.1 was transfected according to the experimental con-
dition. The following Runx2 WT and deletion promoter reporter plasmids (21)
were used: the WT Runx2 0.6-kb fragment and the deletion series (490, 458,
351, 288, 128) fragments. These fragments were cloned in pGL3 basic
luciferase vector (Promega, Madison WI). Cells transfected with either Runx2
promoter luciferase or 208 OC promoter chloramphenicol acetyltransferase
(CAT) reporter constructs along with Hoxa10, Runx2, or control vector were
harvested 24 to 36 h after transfection, and all lysates were assayed for luciferase
or CAT activity according to the manufacturer’s instructions (Promega, Madi-
son, WI). All results were normalized to the luciferase activity resulting from
transfection of the promoterless pGL3 luciferase construct (Promega, Madison,
WI). The OC promoter activity was assayed by using the 208-bp promoter
DNA fragment from rat OC genes cloned in the pCAT basic vector (Promega,
Madison, WI) (32). The percent CAT conversion was the average of values for
six similar transfection samples.
cDNA synthesis and QPCR. RNA was isolated from cultures of MC3T3,
NIH 3T3, and C3H10T1/2 cells by use of TRIzol reagent (Invitrogen, Carls-
bad, CA) according to the manufacturer’s protocol. cDNAs were synthesized
with oligo(dT) primers by use of a SuperScript first-strand cDNA synthesis kit
(Invitrogen) according to the manufacturer’s protocol. Gene expression was
assessed by real-time quantitative PCR (RT-QPCR) using Power SYBR
green PCR master mix (Applied Biosystems, California). Primers used for
PCRs are listed in Table 1.
Electrophoretic mobility shift analysis (EMSA). Recombinant HOXA10 pro-
tein was translated using Promega TNT coupled with a rabbit reticulocyte lysate
system (Promega). WT and mutant oligonucleotides containing the Hoxa10
TABLE 1. Primers for real-time PCR assays
Primer for
indicated gene Sequence
Bone marker primers
(mouse)
BSP
Forward ...................5-GCA CTC CAA CTG CCC AAG A-3
Reverse ....................5-TTT TGG AGC CCT GCT TTC TG-3
ALP
Forward ...................5-TTG TGC CAG AGA AAG AGA GAG A-3
Reverse ....................5-GTT TCA GGG CAT TTT TCA AGG T-3
Runx2
Forward ...................5-CGG CCC TCC CTG AAC TCT-3
Reverse ....................5-TGC CTG CCT GGG ATC TGT A-3
OC
Forward ...................5-CTG ACA AAG CCT TCA TGT CCA A-3
Reverse ....................5-GCG GGC GAG TCT GTT CAC TA-3
Hoxa10
Forward ...................5-TTC GCC GGA GAA GGA CTC-3
Reverse ....................5-TCT TTG CTG TGA GCC AGT TG-3
Primers for ChIP
(rat)
Runx2
Forward ...................5-TCA GCA TTT GTA TTC TAT CCA AAT CC-3
Reverse ....................5-TGG CAT TCA GAA GGT TAT AGC TTT T-3
ALP
Forward ...................5-CCT GTG CAT TTC CCA ACA CGG CGG-3
Reverse ....................5-CCA CTT CCC AGG CAG TGG AGA CAG-3
BSP
Forward ...................5-GTT TAA ATG CTT AAG TCG TTT GC-3
Reverse ....................5-GGC TGT GGG TTC TCA CCA GAA A-3
OC
Forward ...................5-GGC AGC CTC TGA TTG TGT CC-3
Reverse ....................5-TAT ATC CAC TGC CTG AGC GG-3
Control 3 UTR
primers for
ChIP (mouse)
OC
Forward ...................5-GAT CCC ATA TCA GCC AGC AC-3
Reverse ....................5-GAC TGC CCT GGA TCA CAA GT-3
Runx2
Forward ...................5-CGT CCA CCT GTT CCA AAG TT-3
Reverse ....................5-GGC ATT GCC ATT TTC AGT TT-3
BSP
Forward ...................5-CCT TTT CGG TGA TTG CAG TT-3
Reverse ....................5-AAG GTT GAG GGT GTC AGT GG-3
ALP
Forward ...................5-TTG TTC CTC TTG CCT CAG GT-3
Reverse ....................5-TGA CAA TCA CAT GGC CTC TC-3
Control 3 UTR
primers for
ChIP (rat)
OC
Forward ...................5-GCA CTG CAC AGA TGT GGA AC-3
Reverse ....................5-CAG GTT TTC CCT TTC TCA GG-3
Runx2
Forward ...................5-TGC TTT GCA ACC AAA TCA AG-3
Reverse ....................5-TCT GAA GGG AAG CTT TGG AA-3
BSP
Forward ...................5-TGG AAG ATG CTT GAT GAC CA-3
Reverse ....................5-AAG GGG TCA GAG GAC AAG GT-3
ALP
Forward ...................5-CCA GTG TGA TCC CCA GAA CT-3
Reverse ....................5-TGT CTG TAG CAA TCC CAC CA-3
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binding site derived from the Runx2 P1 promoter site 1 (WT, 5G CAT TCA
GAA GGT TAT AGC TTT 3; mutant, 5G CAT TCA GAA GGC GAT AGC
TTT 3 [underlining indicates the HOXA10 binding site, and boldface indicates
the mutation]) were end labeled with [-32P]ATP by use of T4 polynucleotide
kinase (New England Biolabs, Massachusetts). The detailed procedures have
been described previously (34). Anti-HOXA10 (N20) or a nonspecific antibody
(either -actin or normal immunoglobulin G [IgG] as indicated) (Santa Cruz)
were used for the immunoshift studies. Complexes were visualized by autora-
diography of a 6.5% acrylamide gel.
Immunoblotting. Each well of a six-well plate was lysed in 50 l lysis buffer
(2% sodium dodecyl sulfate [SDS], 10 mM dithiothreitol, 10% glycerol, 12%
urea, 10 mM Tris-HCl [pH 7.5], 1 mM phenylmethylsulfonyl fluoride, 1 pro-
tease inhibitor cocktail [Roche], 25 M MG132 [proteosome inhibitor from
Calbiochem]) and boiled for 5 min. Equal amounts of total protein were ana-
lyzed by SDS-polyacrylamide gel electrophoresis and probed with suitable anti-
bodies. Immunocomplexes were detected using Western Lightning chemilumi-
nescence reagent (Perkin Elmer, Boston, MA).
Antibodies. The following antibodies were purchased from Santa Cruz Bio-
technology. HOXA10 N20 (SC-17158) was for chromatin immunoprecipitation
(ChIP) and EMSA, and A20 (5C-17159) was for Western blotting. RUNX2
antibodies were PEBP2A (M-70 [SC-10758]), PEBP2A (C-19 [SC-8566]), and
actin (I-19 [SC-1616]). Mouse monoclonal RUNX2 antibody was a generous gift
from Yoshi Ito and Kosei Ito (National University, Singapore, Republic of
Singapore). Anti-hyperacetylated histone H4 (Penta) and anti-trimethyl histone
H3 (Lys4), clone MC315, were purchased from Upstate Cell Signaling Solutions
(Charlottesville, VA). The mouse monoclonal anti-Xpress antibody was obtained
from Invitrogen (Carlsbad, CA). Mouse monoclonal antibody against RNA poly-
merase II (Pol II) (clone 8WG16) was obtained from Covance (Princeton, NJ)
and used in ChIP studies.
ChIP assays. The procedure for ChIP in primary rat osteoblasts has already
been described (34). Control primer pairs from 3 untranslated regions (UTR) of
the genes were used to verify specific and nonspecific binding of DNA fragments
(Table 1). IgG antibody was used as a control for nonspecific pull-down of
immunocomplexes. Sequential ChIP studies were performed using the primary
pull-down from one antibody, which was divided into equal aliquots for the
second pull-down with antibodies specific for coregulatory molecules. Instead of
being eluted in 1% SDS and 100 mM Na2HCO3 after cross-linking and washing,
immunocomplexes were eluted in 10 mM dithiothreitol. The eluate was further
diluted 1:40 in ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM
EDTA, 167 mM Tris-HCl [pH 8.1], 167 mM NaCl) and used for the second
immunoprecipitations. Aliquots (2 to 3 l) of DNA samples from different
pull-downs were assayed by either radioactive labeling or RT-QPCR using Power
SYBR green PCR master mix (Applied Biosystems, California) for the detection
of specific DNA fragments with primers in the proximal promoters of bone-
related genes that encompass the Hoxa10 binding sites (Table 1).
Immunohistochemistry and immunofluorescence. Long bones from normal
newborn mice were fixed with 4% paraformaldehyde in 0.1 M cacodylate buffer,
pH 7.4, for 48 h, dehydrated, and embedded in paraffin by standard procedures.
Paraffin-embedded tissues (5-m sections) were immunoperoxidase labeled and
blocked by 0.3% H2O2 in absolute methanol for 30 min at room temperature. To
reveal antigens, sections were put in a 1 mM Tris solution, pH 9.0, supplemented
with 0.5 mM EGTA. The sections for RUNX2 immunohistochemistry were
heated in a microwave oven for 10 min after EGTA treatment, while a normal
steaming antigen retrieval method was used for HOXA10. Nonspecific immu-
noglobulin binding was prevented by incubating the sections in 50 mM NH4Cl for
30 min followed by blocking with phosphate-buffered saline supplemented with
1% bovine serum albumin, 0.05% saponin, and 0.2% gelatin. Serial sections were
incubated overnight at 4°C with anti-rabbit RUNX2 (M-70 and C-19) or anti-
goat HOXA10 (N20) antibody diluted (1:100) in phosphate-buffered saline sup-
plemented with 0.1% bovine serum albumin and 0.3% Triton X-100. Equal
amounts of the respective blocking peptides (2 g/ml) for HOXA10 and RUNX2
were also used. Normal IgG was used as a nonspecific control. Immunolabeling
controls were performed by using antibodies preabsorbed with immunizing pep-
tides. Labeling was visualized with the horseradish peroxidase-conjugated sec-
ondary antibody (P448, 1:200; Dako).
MC3T3 cells were plated at a density of 0.6  105 cells/well on gelatin-coated
coverslips in six-well plates. Cells were processed for in situ immunofluorescence
analyses, which were carried out as described previously (39). HOXA10 was
detected by a goat polyclonal antibody at a dilution of 1:100 (Santa Cruz Bio-
technology). The secondary antibody used was Alexa 488–anti-goat antibody
(Molecular Probes) at a dilution of 1:800. For overexpressed HOXA10 protein,
HeLa cells at 0.5  105cells/well on gelatin-coated coverslips were transfected
with 0.5 g of Hoxa10 expression construct, and 24 h after transfection the
coverslip was processed for immunofluorescence study (39). Xpress-HOXA10
was detected by a mouse monoclonal antibody against the Xpress tag at a
dilution of 1:3,000 (Invitrogen). The secondary antibody used was Alexa 568–
anti-mouse antibody (Molecular Probes, Eugene, OR) at a dilution of 1:800.
Slides were examined on a Zeiss Axioplan 2 microscope fitted with epifluores-
cence (Carl Zeiss, Jena, Germany) attached to a charge-coupled-device camera.
Images were saved and processed using Metamorph imaging software, version
6.1 (Universal Imaging, Downingtown, PA).
RNA interference (RNAi) of Hoxa10. The mouse MC3T3-E1 osteoblastic cells
at 30 to 50% confluence were transfected using Oligofectamine (Invitrogen Life
Technologies) with small interfering RNA (siRNA) duplexes specific for murine
Hoxa10 r(CCA AAU UAU CCC ACA ACA A)dTdT and r(UUG UUG UGG
GAU AAU UUG G)dCdG obtained from QIAGEN Inc. (Stanford, CA). Six
different sets of siRNA duplexes at different concentrations were used to eval-
FIG. 1. Hoxa10 expression in relation to osteogenic differentiation.
(A) Premyogenic C2C12 cells were treated with 100 ng/ml BMP2 for
24 h. Total RNA was isolated at different time points (0, 1, 2, 4, 6, 8,
12, 16, 20, and 24 h). Five micrograms of total RNA was reverse
transcribed with oligo(dT) primer and amplified (RT-QPCR) by gene-
specific primers. (Top) Hoxa10 expression (BMP, BMP) was nor-
malized to Gapdh expression (BMP, BMP), and relative transcript
levels were plotted; (bottom) the induction of Runx2 expression with
BMP2 treatment is shown for the same time course. Error bars rep-
resent triplicate analyses of each sample from two independent exper-
iments. (B) Temporal expression of Hoxa10 and the osteogenic mark-
ers Runx2 and ALP during MC3T3 cell growth and differentiation.
cDNAs from different time points were amplified using bone-specific
gene primers (Table 1). Expression values from RT-QPCR were nor-
malized to Gapdh values. Error bars represent triplicate sample anal-
yses from one experiment. Independent experiments exhibited similar
temporal expressions (data not shown).
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uate the target specificity and knockdown efficiency. The cells were also trans-
fected with control siRNA duplexes specific for green fluorescent protein by use
of the same concentrations to check the transfection efficiency. The siRNA
experiment was carried out for 72 h. Total RNA and proteins from the specific
siRNA oligonucleotide-treated, untreated, Oligofectamine-treated and nonspe-
cific-oligonucleotide-treated cells were analyzed by Western blotting and RT-
QPCR. To study chromatin modifications after Hoxa10 siRNA treatment, cells
were harvested 72 h posttransfection and used for immunoprecipitation with
trimethyl histone H3K4 and hyperacetylated H4 antibody for ChIP analyses.
RESULTS
Hoxa10 is a BMP2-responsive gene correlating to the induc-
tion of Runx2-mediated osteogenesis. Hoxa10 was identified as
an early BMP2-responsive gene in an Affymetrix cDNA pro-
filing study of BMP2-mediated osteogenic induction of pre-
myogenic C2C12 cells (3). During the 24-h time course,
Hoxa10 expression clustered into a group of genes in which the
osteogenic transcription factor Runx2 was also present. We
carried out independent experiments in this study and quanti-
tated gene expression by RT-QPCR to validate the microarray
report (Fig. 1A). Both Hoxa10 and Runx2 mRNAs are present
at very low levels in untreated cells, immediately upregulated
by BMP2 within 2 h, and then partly downregulated, but they
exhibit a second spike at 6 h. After the 8-h commitment point
to osteogenesis, when bone phenotypic markers (alkaline
phosphatase and OC) are expressed (3), Hoxa10 mRNA re-
mains at a steady state, while Runx2 continuously increases.
To further evaluate the expression of Hoxa10 and Runx2
during the development of the osteoblast phenotype, we ex-
amined the temporal expression of Hoxa10 during the differ-
entiation of osteoprogenitor MC3T3 cells. Hoxa10 is endog-
enously expressed at low levels in the proliferating cells (day 7)
and is induced four- to fivefold upon the maturation of the
phenotype, concurrent with cellular multilayering (day 10 in
this experiment) (Fig. 1B). Peak mRNA expression levels of
Hoxa10 are transient and downregulated by 50% by day 16, the
onset of mineral deposition in MC3T3 cells. Expression of
Runx2 and alkaline phosphatase phenotypic genes continu-
ously increases during differentiation. These observations sug-
gest that Hoxa10 expression is important at the early stages of
osteoblast differentiation. We further showed that either treat-
ment of pluripotent C3H10T1/2 cells with BMP2 or growth of
adherent bone marrow cells in osteogenic media results in a
twofold increase in Hoxa10 concomitant with the expression of
the osteoblast phenotype (data not shown). These studies im-
plicate HOXA10 in establishing early events in the develop-
ment of the osteoblast phenotype.
To appreciate the role of HOXA10 in osteogenesis in vivo,
we examined its expression in bone cell populations in situ in
relation to endochondral bone formation and skeletal devel-
opment. Sections of long bones and vertebrae from newborn
mice were treated with specific antibodies to detect RUNX2
and HOXA10 (Fig. 2). We found strong expression of
HOXA10 in the periosteum, the hypertrophic chondrocyte
zone of the growth plate, and osteoblasts on all bone surfaces.
FIG. 2. Coexpression of HOXA10 and RUNX2 in vivo and in vitro. (A) HOXA10 and RUNX2 are visualized in hypertrophic chondrocytes
and osteoblast lineage cells in long bones and vertebrae as indicated. Immunohistochemistry was performed using anti-HOXA10 antibody and
anti-RUNX2 antibody. For nonspecific controls, normal rabbit IgG was substituted for primary antibody, and blocking peptides specific for the
HOXA10 and RUNX2 antibodies were used. Bone and vertebra sections are shown at 10 and 40 magnification as indicated for the boxed areas
at the growth plate and the primary spongiosa. Trabeculae show robust expression of both proteins in surface osteoblasts. The first column shows
peptide blocking controls (magnification, 10). (B) In situ immunofluorescence examination of endogenous HOXA10 protein in MC3T3 cells to
demonstrate nuclear staining with few cytoplasmic foci using the Santa Cruz antibody. (C) Nuclear localization of transfected Xpress-tagged
HOXA10 is also observed for HeLa cells detected with anti-Xpress antibody (see Materials and Methods). DAPI, 4,6-diamidino-2-phenylindole.
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RUNX2 was also expressed in these cell populations. Weak
expressions of HOXA10 and RUNX2 were found in the flat-
tened cells that represent the prehypertrophic chondrocyte
phenotype. It is noteworthy that both HOXA10 and RUNX2
were absent from the epiphyseal chondrocytes that represent
permanent hyaline cartilage. Similar observations were made
for vertebrae tissue. We conclude from these studies that
RUNX2 and HOXA10 are expressed in osteogenic lineage
cells and maturing chondrocytes at the growth plate in both the
axial and appendicular skeletons.
While most immunohistochemical staining is nuclear, some
hypertrophic chondrocytes and osteoblasts have cytoplasmic
staining representing either background or specific HOXA10
staining. To address a potential artifact of cytoplasmic staining,
we examined the endogenous localization of HOXA10 by in situ
immunofluorescence in isolated osteoblasts. Punctate nuclear
staining was observed, with a few foci detected in the cytoplasms
of MC3T3 cells (Fig. 2B). However, 100% nuclear localization
was observed with exogenously expressed HOXA10 protein in
HeLa cells by use of the Xpress tag antibody (Fig. 2C). These
findings indicate that the localization of the HOXA10 isoform
with transactivation activity is nuclear.
The coordinate BMP2 induction of Hoxa10 and Runx2 in
response to BMP2-induced osteogenesis in several cell models,
taken together with the profiles of expression of these genes
during the maturation of MC3T3 cells as well as their coex-
pression in osteogenic lineage cells, suggests a functional rela-
tionship between RUNX2 and HOXA10.
The P1 bone-related promoter of Runx2 and the endogenous
Runx2 gene are regulated by HOXA10. As activating signals on
the Runx2 promoter during early stages of embryonic devel-
opment are limited, we pursued the characterization of a
Hoxa10 regulatory element in the bone-related Runx2 P1 pro-
moter. Examination of the Runx2 0.6-kb promoter, which has
been studied for its regulation in osseous and nonosseous cells,
revealed the presence of three putative Hox consensus se-
quences. Two TTAT-containing core sequences (4, 24) and
one sequence with a TTAC core (72), which binds HOXA9
well but HOXA10 with a low frequency (4, 73), are present in
the proximal promoter (Fig. 3A). These sequences differ from
the TAAT binding site for homeodomain proteins of the MSX
and DLX classes (34, 45). To identify the HOXA10-responsive
regulatory element(s) in the Runx2 gene, deletion mutation
analyses were performed with both NIH 3T3 (nonosseous) and
MC3T3 (osseous) cells cotransfected with Runx2 promoter
deletion fragments and HOXA10. The endogenous protein
levels of HOXA10 are slightly higher in the MC3T3 preosteo-
blasts than in the NIH 3T3 fibroblasts (Fig. 3B, control lanes)
which may be contributing to the basal expression of the pro-
moter constructs in MC3T3 cells, where the 351 fragment is
FIG. 3. HOXA10 directly regulates Runx2 promoter activity and transcription. (A) Schematic representation of the deletions of the 0.6-kb
Runx2 promoter with the firefly luciferase reporter gene. The full-length 0.6-kb promoter contains two Hoxa10 putative binding sites (site 1 and
site 2) having the core TTAT motifs. Deletion clones 490- and 458-Luc contain only site 1, whereas clones 351-, 288-, and 108-Luc are
devoid of Hoxa10 binding sites. (B) Western blots of endogenous and exogenous HOXA10 protein levels in nonosseous (NIH 3T3) and osseous
(MC3T3) cells. For detection of endogenous and exogenous HOXA10 protein, anti-HOXA10 (N20; Santa Cruz Biotech Inc.) was used. , anti-.
(C) A functional Hoxa10 resides in the proximal Runx2 promoter. Runx2 promoter deletion mutant constructs were cotransfected with 400 ng of
either backbone vector (control representing basal promoter activity [open bars]) or Hoxa10 expression construct (treated [solid bars]). Runx2
promoter activities are calculated from relative luciferase values for both NIH 3T3 and MC3T3 cells. All transfections were performed in triplicate.
RLU, relative light units. (D) Two nucleotide mutations (TTAT to CGAT) were constructed in the distal (site 2) and proximal (site 1) Hoxa10
binding motifs in the 0.6-kb Runx2 P1 promoter as illustrated. Hoxa10-mediated activation for WT/mutant is indicated.
VOL. 27, 2007 MECHANISMS FOR HOXA10 REGULATION OF OSTEOGENESIS 3341
reduced 20% (Fig. 3C). In the presence of exogenous
HOXA10, a 2- to 2.5-fold increase in promoter activity of the
600, 490, and 458 fragments is observed, suggesting that
the proximal TTAT site 1 is sufficient for HOXA10 regulation
of Runx2 (Fig. 3C). Furthermore, complete loss of HOXA10
responsiveness occurs with the 351 Runx2-Luc fragment,
which lacks the putative site 1 for HOXA10 binding. Further-
more, mutation of site 1 blocked HOXA10-mediated tran-
scriptional activation (Fig. 3D). The site 2 mutation had no
effect on HOXA10 induction of Runx2, i.e., the construct re-
tained the same 2.5-fold activation level as the WT. The TTAC
core site, located at 420/417, cannot be functional, as the
site 1 mutation showed no HOXA10-induced change in pro-
moter activity. Taken together, these results are consistent with
the location of a functional Hoxa10 site in the proximal pro-
moter fragment at353/351, a regulatory element mediating
HOXA10 activation of the Runx2 P1 promoter.
Sequence-specific binding of HOXA10 to the proximal reg-
ulatory motif was validated in EMSA by WT and mutant oli-
gonucleotide binding studies (Fig. 4A and B). Confirming the
mutation studies, site 2 does not form a HOX protein-DNA
complex with osteoblast nuclear extracts (Fig. 4B). In con-
trast, site 1 binds in vitro-transcribed and -translated (IVTT)
HOXA10 protein and HOXA10 from nuclear extracts of os-
teoblasts, as indicated by antibody supershifts (Fig. 4B). To
rule out the possibility of redundant HOX protein binding to
site 1 because other HOX factors are expressed in osteoblasts
(20, 30), we further examined the interaction of other paralo-
gous HOX proteins expressed in MC3T3 cells with Runx2 site
1. Antibody specificities were established by testing IVTT
HOXA10 protein bound to probe with supershift analyses us-
ing antibodies specific to other Abd B class proteins. None of
these antibodies cross-reacted with HOXA10 (Fig. 4C, left
panel), nor did they supershift/block shift the HOXA10 com-
plex from nuclear extracts bound to Runx2 site 1 (Fig. 4C, right
panel). In conclusion, the deletion and site-directed mutagen-
esis of putative Hox elements in the 0.6-kb Runx2 promoter
demonstrates that HOXA10 protein binds preferentially to the
Runx2 TTAT site 1.
To address the biological significance of the HOXA10-me-
diated positive regulation of the Runx2 gene at the onset of
osteoblast differentiation, cellular levels of HOXA10 were in-
hibited by siRNA knockdown in two osteogenic cell models.
Preosteoblastic MC3T3 cells were treated with several Hoxa10
siRNA duplex oligonucleotides for 72 h, which resulted in the
inhibition of HOXA10 cellular protein levels compared with
the nonsilencing duplex control. Figure 5A shows results for
two siRNAs, one of which only modestly decreased HOXA10
protein (siRNA2; decrease of 10 to 15% from densitometry
measurements), while siRNA1 exhibited a robust dose-depen-
dent inhibitory effect on HOXA10 and also caused a significant
dose-related decrease in RUNX2 protein (Fig. 5B).
The potency of HOXA10 in regulating Runx2 at the onset of
BMP2-induced osteogenesis was examined with C2C12 cells
(Fig. 5C). Cells were first treated with siRNA for 48 h, which
was followed by BMP2 for 2 h. Hoxa10 siRNA resulted in a
50% knockdown of Hoxa10, a decrease which prevented the
twofold BMP2 induction of Hoxa10 mRNA in the control
(absence of Hoxa10 siRNA). Runx2 was reduced nearly 75% by
Hoxa10 siRNA in the absence of BMP2. In the presence of
BMP2 and Hoxa10 siRNA, Runx2 was not induced to a level
over that seen for the control. However, the inhibition was less
(33% decrease) than in the absence of BMP2 (	50% de-
crease). This finding is likely the consequence of BMP2 induc-
tion of other transcription factors that can upregulate Runx2.
Thus, we were prompted to examine levels of Dlx3, a BMP2
early response gene in this cell model (35). Dlx3 was induced
over the control in the presence of Hoxa10 siRNA and BMP2
(data not shown). These studies define HOXA10 as a signifi-
FIG. 4. Specificity of the Hoxa10 site 1 for HOXA10 interactions.
(A) Oligonucleotide sequences are shown for the WT and the Hoxa10
site mutations and compared to that for the mouse consensus optimal
Hoxa10 binding site (4). Underlining indicates the core binding site;
lowercase indicates mutant nucleotides. (B) DNA binding activity of
HOXA10 is demonstrated by EMSA. Ten femtomoles of labeled dou-
ble-stranded oligonucleotides derived from the WT or mutant (Mut)
probe as indicated was incubated with 2 l of IVTT HOXA10 or 5 g
of MC3T3 nuclear extract (NE). Self-competition (Self), antibody su-
pershift, and nonspecific antibody (NS Ab) controls are shown. The
mutant double-stranded oligonucleotide for Hoxa10 does not bind
nuclear proteins. The top unlabeled arrows indicate the supershifted
band; the lower unlabeled arrows show the position of the HOXA10-
specific band, below which is a nonspecific complex (arrows labeled
NS). , anti-; C, control. (C) IVTT of indicated HOX proteins is
complexed with the Hox site 1 in Runx2 to show the specificity of the
HOXA10 antibody. Nuclear extracts of MC3T3 osteoblasts were used
in EMSA studies to show the specificity of the HOXA10 interaction
(arrow) with the site 1 Runx2 probe. GFP, green fluorescent protein;
EV, empty vector.
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cant regulator of Runx2 transcriptional activity and gene ex-
pression.
Functional recruitment of HOXA10 to promoters of Runx2
and other osteoblast-related genes. To gain further insight into
the in vivo regulation of Runx2 transcription by HOXA10
during the development of the osteoblast phenotype, we per-
formed ChIP assays with primary rat calvarial osteoblasts,
which undergo a well-documented sequence of maturation
stages (59). Western blot analysis for RUNX2 and HOXA10
protein levels during the differentiation time course shows that
a low basal level of HOXA10 protein is present in proliferative
osteoblasts (day 4), while RUNX2 protein is not observed until
day 6 (Fig. 6A). When bone-like nodules form on day 10,
HOXA10 is upregulated twofold, increases again on day 12,
and remains at a constitutive level into the mineralization stage
(day 20). RUNX2 protein levels increase continuously during
osteoblast maturation but are reduced on day 20 (heavily min-
eralized cultures). These findings emphasize that HOXA10 is
present in osteoprogenitors prior to RUNX2 protein appear-
ance and that HOXA10 may function throughout differentia-
tion.
The timing of recruitment of HOXA10 to the Runx2 gene in
relation to transcription was determined by ChIP assays at the
indicated days during differentiation (Fig. 6B). Trace levels of
HOXA10 above those for the IgG control were observed on
days 4 and 5 in different experiments. Consistently, we found
that RNA Pol II and HOXA10 were robustly associated with
the promoter, beginning on day 6, when RUNX2 protein was
first detected in this experiment (Fig. 6B). This coordinate
occupancy was reproducible over multiple time courses (data
not shown). HOXA10 remained bound to the Runx2 promoter
but dissociated on day 20, the late mineralization stage, a
finding consistent with decreased RUNX2 protein levels in the
cells (Fig. 6A) and decreased RNA Pol II association with the
promoter (Fig. 6B). On the other hand, RUNX2 association
with its own promoter gradually increased from day 6 to day 20
in late mineralization, reflecting its role in maintaining physi-
ologic transcription by autoregulation (21). Thus, HOXA10
contributes both to the significant activation of Runx2 expres-
sion throughout the early stages of osteoblastogenesis and to
the regulation of physiologic levels in mature osteoblasts by
dissociation from the Runx2 promoter.
FIG. 5. RNAi of Hoxa10 in MC3T3 and C2C12 cells inhibits Runx2 and osteogenic gene expression. (A) Knockdown of Hoxa10 in MC3T3-E1
cells by two sets of Hoxa10 siRNA duplexes and nonspecific controls (NS). The lower panel shows densitometric quantitation of HOXA10
knockdown when cells were isolated 72 h after siRNA treatment. (B) Preosteoblast MC3T3 cells at 30 to 50% confluence were transfected with
siRNA1 specific for murine Hoxa10 at different concentrations (50, 100, and 200 nM). (Top) The Western blot shows the knockdown of RUNX2
protein upon treatment with Hoxa10-specific siRNA duplexes. UT, untransfected; NS, nonsilencing duplexes (used as controls). Densitometry
shows reductions of RUNX2 protein upon knockdown of Hoxa10. (C) C2C12 cells were plated on day 0 at 30 to 40% confluence and treated with
Hoxa10 siRNA or nonspecific siRNA [siRNA(NS)] (100 nM) for 48 h. After the medium was changed, BMP2 (100 ng/ml) was added to induce
Hoxa10 and Runx2 for 2 h. mRNA levels were assayed by RT-QPCR. White bars represent the control for the treatment as indicated. GFP, green
fluorescent protein; , anti-.
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ChIP studies allow for assays of transcription factors asso-
ciated with different promoters in the same sample. We there-
fore examined the promoters of several osteoblast genes for
potential Hoxa10 binding sites and designed primers to amplify
the DNA of the appropriate promoter domain. Table 2 shows
the putative sequences. We examined the direct regulation
of the osteoblast-specific OC gene, which is highly regulated by
RUNX2 (40). A Hox binding site was located in the proximal
208 promoter segment, which exhibits tissue-restricted ex-
pression (37) (Fig. 7A). Using a 208 OC-CAT reporter con-
struct, we found a two- to threefold increase in promoter
activity in response to HOXA10 in multiple experiments (Fig.
7B). By ChIP analysis (Fig. 7C), we found that HOXA10 is
associated with OC chromatin 24 h prior to RUNX2 associa-
tion. During osteoblast differentiation, both HOXA10 and
RUNX2 binding were enhanced on days 8 and 9, when OC
mRNA first began to accumulate (Fig. 7D), consistent with
increased Pol II binding on day 9 (Fig. 7C). After this initial
induction of OC, HOXA10 association with the OC promoter
diminished in the matrix maturation and mineralization stages,
while RUNX2 remained present on OC chromatin. The coor-
dinate increase in HOXA10 and RUNX2 binding to OC
prompted us to examine the combined effects of HOXA10 and
RUNX2 on OC promoter activity. We found an additive effect
on promoter activity as a result of the coexpression of the
factors (Fig. 7B), suggesting that the Hoxa10 and Runx2 regu-
latory elements function independently on the OC promoter,
not synergistically. Taken together, these results demonstrate
HOXA10 supports the regulation of OC expression earlier
than RUNX2 and significantly contributes to OC-induced
mRNA.
We also examined the promoters for alkaline phosphatase
(ALP) and bone sialoprotein (BSP) and found Hoxa10-regu-
latory elements (Table 2 and Fig. 8). In proliferating primary
osteoblasts, ALP (Fig. 8A) and BSP (Fig. 8B) are expressed,
but at low levels. Association of HOXA10 with the ALP and
BSP promoters was confirmed by ChIP assay with the osteo-
progenitor cells (day 4) as well as with postproliferative mature
osteoblasts (days 12 and 20). Interestingly, HOXA10 associa-
tion with the promoter of ALP, the early marker of osteoblasts,
was most prominent on day 4 and reduced on day 20, when
ALP mRNA is downregulated. In contrast, both HOXA10
binding to the BSP promoter and BSP expression (mRNA)
increased during differentiation. These observations suggest
that HOXA10 directly regulates genes independent of
RUNX2 binding.
These ChIP studies reveal that the recruitment of RUNX2
to most gene promoters continuously increases during differ-
entiation, with similar profiles in each case (Fig. 8C). Figure 8C
summarizes the profiles (from densitometry measurements of
the ChIPs) of RUNX2 and HOXA10 association with four
gene promoters. In contrast to RUNX2, HOXA10 has distinct
profiles of association/dissociation with individual gene pro-
moters during differentiation. It is notable that HOXA10 as-
sociation to the gene promoters is critical to gene regulation
independent of HOXA10 cellular levels (Fig. 8C, left panel).
These differences may reflect very dynamic functional charac-
teristics of HOXA10 promoter binding in relation to the reg-
ulation of the transcription of osteoblast genes at stages of
osteoblast phenotype development. We conclude from these
studies that Hoxa10 functional elements are present in multi-
ple osteoblast genes, including the OC, bone sialoprotein, and
alkaline phosphatase genes, contributing to their regulated
expression.
HOXA10 regulates osteoblast genes both dependent on (in
MC3T3 cells) and independent of (in Runx2 null cells)
RUNX2. The ChIP studies (Fig. 6, 7, and 8) suggest that
HOXA10 may regulate osteoblast genes that are significant
functional components of bone, either synergistically, by in-
creasing Runx2 expression, or directly, through Hox regulatory
motifs. We therefore examined the consequences of the deple-
tion of Hoxa10 on the endogenous expression of these skeletal
markers of osteoblast differentiation by RT-QPCR (Fig. 9A).
MC3T3 cells were treated with Hoxa10 siRNA for 48 h, which
reduced Runx2 gene expression threefold. Dose-dependent de-
creases of the early osteoblast markers ALP and BSP were also
observed, as was a twofold reduction in OC mRNA. Exoge-
FIG. 6. HOXA10 protein and recruitment to the Runx2 promoter
in primary calvarial cells during osteoblast growth and differentiation.
(A) Western blot analyses for RUNX2 and HOXA10 protein expres-
sion are shown during stages of growth and differentiation of isolated
primary calvarial osteoblasts as indicated (antibody information is pro-
vided in Materials and Methods). Protein profiles of actin demonstrate
equivalent amounts of total protein loaded in the gel. (B) ChIP studies
of the Runx2 proximal promoter locus during growth and differentia-
tion. The top panel illustrates the positions of regulatory elements and
primers used to amplify the Runx2 promoter-specific DNA fragments.
Open arrow, RNA Pol II; solid arrow, HOXA10 and RUNX2 occu-
pancy. For the middle panel, ChIP analysis was performed on the
indicated days with antibodies for HOXA10, RUNX2, or RNA Pol II
(see Materials and Methods). One percent of the soluble chromatin
fraction was taken as the input fraction. IgG is shown as an antibody
control. The lower panel shows the control for ChIP primer specificity.
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nous expression of HOXA10 in MC3T3 cells (Fig. 9B) shows
that Runx2 and ALP expression is increased twofold, while the
mature osteoblast-related genes OC and BSP are induced be-
tween five- and eightfold.
To address the possibility of the direct regulation of osteoblast
genes, we tested the competency of HOXA10 to induce their
expression independent of RUNX2 by using a TERT-immortal-
ized preosteoblastic cell line derived from Runx2 null mice (1)
(Fig. 9C). Cells were transfected with Hoxa10 and/or Runx2 ex-
pression vector, and total cellular RNA was analyzed 24 h later.
Expression profiling by real-time PCR revealed that HOXA10
induced OC, ALP, and BSP to an extent the same as that seen for
their induction by RUNX2 (three- to fourfold for OC or BSP and
five- to sixfold for ALP). The presence of HOXA10 and RUNX2
together resulted in an additive induction for OC and BSP, genes
whose expression continues to increase during differentiation
(Fig. 7 and 8), but not ALP (Fig. 8).
HOXA10 activation of osteogenic genes OC, ALP, and BSP
in Runx2 null cells, taken together with the association of
HOXA10 with binding elements in these promoters, supports
a RUNX2-independent direct role for HOXA10 in promoting
osteoblast differentiation. However, these promoters are also
Runx2 responsive, and HOXA10 directly induces Runx2,
thereby contributing to HOXA10 RUNX2-dependent tran-
scription of osteoblast genes. The BMP2-initiated induction of
Hoxa10, Runx2, and other transcriptional factors (e.g., DLX3
and DLX5) indicates that these factors all contribute specific
regulatory functions to support bone formation. This combi-
natorial control is schematically illustrated in Fig. 9D.
HOXA10 contributes to chromatin modification of osteo-
blast target genes for induced transcription. The early recruit-
ment of HOXA10, prior to RUNX2, on the OC, ALP, and BSP
gene promoters suggests that HOXA10 may contribute to re-
modeling the chromatin of these phenotypic genes. The re-
modeling of chromatin structure is mediated in part by en-
zymes that topologically alter DNA interactions with histones
or that covalently modify the core histone proteins H3 and H4
(41). Acetylation of histone H4 and H3K4 methylation are
modifications that strongly correlate with transcriptionally ac-
tive chromatin (10, 75, 77). To test this hypothesis, we exam-
ined the effects of Hoxa10 depletion on histone acetylation and
H3K4 methylation of gene promoters, which reflect transcrip-
tionally active chromatin. Cells were treated with Hoxa10-spe-
cific siRNA for 72 h (Fig. 10A), and these chromatin modifi-
cations were assayed by ChIP analysis for the four bone
phenotypic genes (Fig. 10B). We confirmed a 50% knockdown
of Hoxa10 by siRNA and a 50% reduction in HOXA10 binding
to OC, ALP, and BSP promoters but a modest decrease in the
recruitment of HOXA10 to the RUNX2 promoter (Fig. 10B,
left panels). We observed a significant 50% reduction in the
acetylation of OC, BSP, and Runx2 chromatin but a modest
decrease in ALP chromatin acetylation in cells treated with
Hoxa10 siRNA relative to control levels (nonsilencing siRNA)
(Fig. 10B). On the other hand, we found in multiple studies
(n 
 3) a significant decrease in the H3K4 methylation of ALP
and BSP, while the methylation of OC and Runx2 chromatin
was less decreased.
Upon RNAi-mediated depletion of HOXA10, we found an
impairment of histone modifications in the chromatin of the
Runx2, OC, ALP, and BSP genes, suggesting that coregulatory
proteins with histone acetyltransferase (HAT) activity may be
present in a HOXA10 complex associated with chromatin. To
address this mechanism of chromatin remodeling by HOXA10
binding to target genes, we examined the association of co-
regulatory proteins having HAT activity, p300 and CBP, with
HOXA10 (Fig. 10C). We performed sequential chromatin im-
munoprecipitation studies (ChIP-reChIP) to determine the in
vivo interactions of HOXA10 with coactivator proteins on the
TABLE 2. HOXA10 binding motifs in bone-specific promoters
Promoter
Nucleotide at indicated positiona
Binding Functionalactivity4 3 2 1 1 2 3 4 5 6 7
Hoxa10 consensus A A T T T T A T T A C
Runx2 (mouse)e A A G G T T A T A G Cb  
Runx2 (rat)e T T C A T T A T T A Tc  
A A C C T T A C A G Gd  
OC (mouse) C T G C T T A C A T C
OC (rat) C T G C T T A C A T T
BSP (mouse) T A T T T T A T T T G
BSP (rat) T A G T T T A T T T T
T T A T T T A T A G A
ALP (mouse) C T G C T T A T G A A
ALP (rat) G T C A T T A T A A C
T C G T T T A T G C A
T T A C T T A T A G G
a Osteoblast gene sequences were obtained from the NCBI database. HOXA10-allowed nucleotides (4 to 1 and 5 to 7) outside the core (1, T; 2, T; 3, A; 4, T
or C) are as follows for the indicated positions, as detailed in the work of Benson et al. (4):1, T	G;2, T	G;3, A	T	G;4, A	G
 T; 5, T	G	A; 6, A	G	C;
7, C	A 
 G. HOXA9 can bind to TTAC as well as to TTAT sites, as shown by Shen et al. (72–74).
b Runx2 functional Hoxa10 sequence (site 1) (Fig. 3 and 4).
c HOXA10 binds IVTT protein but not in nuclear extracts and is nonresponsive to Runx2 site 2 (Fig. 3 and 4).
d Uncharacterized Runx2 binding site with TTAC motif (419/416).
e The corresponding HOXA10 binding site indicated in nucleotides across species and obtained for different bone marker genes (Runx2, OC, BSP, and ALP).
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Runx2 and OC promoters in ROS 17/2.8 cells. These cells
robustly express endogenous bone-related factors. A first ChIP
was performed with HOXA10 antibody, followed by pull-down
with antibodies specific to each coregulatory protein (Fig.
10C). Although the interaction of HOXA10 is greater with the
OC gene than with the Runx2 promoter, p300 and CBP are
found in the HOXA10 complex associated with both genes.
These results demonstrate that the presence of HOXA10 on
bone target genes can contribute to epigenetic alterations in
chromatin that favor transcription (summarized in Fig. 10D).
DISCUSSION
In this study we have defined a principal role for HOXA10
in contributing to osteoblast cell fate and differentiation.
Hoxa10, which is essential for skeletal patterning, is character-
ized in our studies as an activator of Runx2 and three pheno-
typic genes (ALP, BSP, and OC) that represent progressive
stages of osteoblastogenesis. Our data support the concept that
HOXA10 functions in initiating osteogenic gene expression
but that the bone phenotype is not fully established until Runx2
is expressed. The evidence includes the following: (i) the find-
ing that Hoxa10 and Runx2 are immediate-response genes to
the BMP2 morphogenetic signal and exhibit similar expression
profiles during the induction of the osteoblast phenotype in
C2C12 cells; (ii) the exhibition by both genes of robust expres-
sion in osteoprogenitors, growth plate chondrocytes, and os-
teoblasts in vivo, which further demonstrates the coexpression
of HOXA10 and RUNX2 in osteogenic lineage cells in vivo;
(iii) the activation of Runx2 transcription by HOXA10 in mes-
enchymal cells; (iv) the early recruitment of HOXA10 to target
gene chromatin during induction of the osteoblast phenotype,
which has consequential effects on acetylation and H3K4
methylation, a signature of active chromatin; and (v) RNAi-
directed depletion and exogenous expression of HOXA10,
which confirm a coordinate change in endogenous expression
of Runx2 and osteoblast genes. Further, the demonstration
that HOXA10 can directly regulate osteogenic genes in the
absence of Runx2 (studies performed with Runx2/ cells)
identifies HOXA10 as a contributor to bone formation inde-
pendent of Runx2. Together, these results indicate that
HOXA10 plays a pivotal role at the onset of osteoblast com-
mitment and may be a significant factor in contributing to
osteoblastogenesis by dynamic regulation of osteoblast genes
throughout stages of differentiation. Thus, Hoxa10 has a key
role in promoting bone tissue formation beyond its require-
ment for patterning the embryonic skeleton.
Our findings suggest HOXA10 functions in a linear pathway
FIG. 7. HOXA10 is recruited to the OC promoter to directly regulate gene expression. (A) Activation of OC gene transcription by HOXA10.
Schematic representation of rat proximal OC promoter segment illustrating the location of the only Hoxa10 consensus motif in the 208-bp 5 OC
fragment. Arrows are the forward (198) and reverse (28) OC primers used in ChIP analysis. (B) The mouse preosteoblast cell line MC3T3-E1
was cotransfected with either empty vector (control) or Hoxa10 and Runx2 expression plasmids as indicated and with the proximal OC promoter
(208 OC-CAT) by use of FuGENE6 (Roche Molecular Biologicals). Control cells contained the indicated amount of backbone plasmid (pGL3).
Cells were harvested 24 h posttransfection for CAT assay. Promoter activity was calculated from values equivalent to those for six samples and
expressed as percent CAT activity. (C) In vivo occupancy of HOXA10 on the OC gene. Cross-linked chromatin samples from primary rat
calvarium-derived osteoblast cultures at the indicated stages of differentiation (days 4, 5, 8, 9, 12, and 20) were used for immunoprecipitation
reactions with 2 g of HOXA10, RUNX2, Pol II, and nonspecific antibody (IgG). The pull-down DNA fragments were purified and assayed by
PCR. Input represents 1% of each chromatin fraction used for immunoprecipitation. The ChIP data presented are representative of multiple
experiments in which all the time point data were derived from the same osteoblast preparation. The lower panel shows the control for ChIP primer
specificity. (D) Expression of OC mRNA (QPCR) during differentiation of primary calvarial osteoblasts at the indicated days. C/EBP, CCAAT/
enhancer-binding proteins.
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with RUNX2 to promote bone formation as well as indepen-
dently of RUNX2. Our model (Fig. 9D) proposes that
HOXA10 functions as an immediate early response gene to the
BMP2 signal for the initiation of osteogenic gene regulation
and provides an amplification step for RUNX2-induced ex-
pression to establish the osteoblast phenotype. As other
BMP2-induced transcription factors regulate Runx2 and os-
teoblastic genes (e.g., homeodomain proteins [MSX2, DLX3,
and DLX5], TCF/LEF1, AP-1, OSTERIX, CCAAT/enhancer-
binding proteins [encoded by C/EBP], and ATF4) (22, 28, 45,
82, 83, 86), a compelling question is that of the hierarchy of
HOXA10, RUNX2, and these other factors in regulating gene
expression for bone formation. Null mouse models have iden-
tified OSTERIX function later than RUNX2 (56). From a
developmental perspective, BMP/TGF, Wnt, and HOX sig-
naling interactions are documented (5, 62), and all of these
proteins contribute to bone development. From a gene regu-
lation perspective, a hierarchy of transcriptional control can be
better deduced by understanding the ordered recruitment of
factors to gene promoters and the temporal levels of the reg-
ulatory factors during osteoblast differentiation. Abd B class
Hoxa10, Msx2, and the distal-less Dlx3 genes are induced
within a few hours, while other factors (e.g., Dlx5 and C/EBP)
are induced later (after 8 h) in the C2C12 model. Recent
studies provide evidence from ChIP studies for a homeodo-
main protein regulatory network for osteoblast commitment
and differentiation (35). Here we show HOXA10 to be asso-
ciated with bone promoters prior to RUNX2, suggesting that it
contributes to the initiation of the osteoblast phenotype. How-
ever, increased HOXA10 binding appears to be coordinated
with increased recruitment of Runx2, homeodomain proteins,
and other factors postproliferatively for accumulation of
mRNA, thereby establishing the bone phenotype (35). The
selective temporal binding of HOXA10 to promoters reflects
binding and dissociation during differentiation. This is in con-
trast to the continual increase in RUNX2 binding to promot-
ers, suggesting that HOXA10 has a very dynamic regulatory
function for regulating osteogenic gene expression during os-
teoblast differentiation.
We found modifications of histones at the level of chromatin
in response to altered HOXA10 expression, indicating a re-
modeling of the transcriptional machinery that is necessary for
in vivo gene regulation. HOXA10 recruitment to bone pro-
moters prior to a significant accumulation of mRNA but after
Pol II association emphasizes a functional role for HOXA10
increasing transcription through chromatin remodeling. This is
FIG. 8. Hoxa10 regulatory elements are present in the ALP (A) and BSP (B) genes. ChIP assay was performed with primary rat calvarial
osteoblasts by use of the indicated antibodies at the proliferation stage (day 4) and the differentiation stages (days 12 and 20, early and mature
osteoblasts in mineralized matrix). HD, homeodomain. (Top) Illustration of Hoxa10 sites and locations of primers (arrows) used to detect the
association of HOXA10 with the ALP and BSP promoters; (bottom) ChIP quantitated by radioactivity with control primers shown below (left) and
expression of ALP and BSP genes by RT-QPCR (right). (C) Summary profiles of cell protein levels and recruitment of HOXA10 and RUNX2 to
four bone promoters. The data represent densitometric values obtained from Western blot and ChIP experiments normalized to actin and IgG
values, respectively.
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supported by knockdown of HOXA10 reducing histone acet-
ylation and H3K4 methylation, which are associated with ac-
tive transcription and by HOXA10 and p300/CBP coassocia-
tion on the Runx2 and OC promoters (ChIP-reChIP studies).
Earlier studies have reported that HOX factors can modify
transcriptional activation and repression by interacting with
p300/CBP (14, 71). Our studies have focused on HOXA10 in
supporting chromatin remodeling for the activation of osteo-
blast-related genes, as was shown for p21 (9). Equally impor-
tant is the fact that HOXA10 can promote histone deacetyla-
tion by recruiting histone deacetylase 2 and SIRT2 histone
deacetylases to repress gene transcription (67). Histone
deacetylase-HOXA10 interactions would reverse HAT activity
and could be operative in osteoblasts for HOXA10 to mediate
either activation or attenuation of gene expression. Such mech-
anisms are important for HOXA10 suppressor function in un-
differentiated myeloid cells and HOXA9 regulation of neovas-
cularization (2, 51, 65, 78). In addition to coregulatory factors
that modify chromatin, the other well-characterized partner
proteins for the Abd B HOX proteins, PBX1 and MEIS, both
having homeodomain protein modules, form complexes with
HOX proteins and also bind to DNA to regulate repressor and
enhancer activities of Hox genes. HOXA9, HOXA10,
HOXA11, HOXD12, and HOXB13 each have different prop-
erties of interaction with these coregulators (52, 61, 72–74).
For example, high-affinity DNA binding can be achieved when
HOXB9 and HOXA10 proteins are dimerized with PBX1.
While our forced-expression and siRNA knockdown studies
show that HOXA10 has anabolic activity on osteoblast gene
expression, how these endogenous partner proteins influence
the HOXA10-mediated expression of osteoblast genes is a
provocative question.
The specificity of HOXA10 for regulating osteoblast differ-
entiation should be considered in relation to Hox nonparalo-
gous and paralogous genes, which are known to overlap in
expression in some tissues but can have preferential activities
(15, 17, 27). For example, HOXA10 and HOXD10 regulate
the skeleton but may exhibit specific gene regulation properties
(36, 49, 79). Also, HOXA10 and HOX11 homeobox proteins
are equivalent for axial but not appendicular skeletal develop-
FIG. 9. HOXA10 regulation of osteoblast phenotypic genes dependent on and independent of RUNX2. (A) Transcript levels of bone
phenotypic markers are decreased by Hoxa10 siRNA treatment at the indicated doses. RT-QPCR mRNA expression profiles in Hoxa10
siRNA-treated (100 and 200 nM) MC3T3 cells. The relative mRNA expression profiles of the endogenous marker genes were normalized to Gapdh
expression profiles. Error bars are means  standard deviations from triplicate samples. (B) Forced expression of Hoxa10 (200 ng) for 24 h induces
expression of bone phenotypic genes (RT-QPCR analyses of six samples). (C) A Runx2/ TERT-immortalized stable cell line was transfected with
400 ng cytomegalovirus-driven Hoxa10, 200 ng Runx2, or both expression plasmids for 24 to 36 h (six samples). Cell layers were harvested for total
cellular RNA and analyzed for expression of indicated genes by RT-QPCR. (D) Schematic illustration of the BMP2-induced HOXA10,
homeodomain proteins DLX3/DLX5, and RUNX2 gene expression representing the initiation phase of osteogenesis. Together these genes
establish the osteoblast phenotype by direct and Runx2-dependent activities on target genes.
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FIG. 10. siRNA knockdown of Hoxa10 decreases histone acetylation and H3K4 methylation of osteogenic genes. (A) MC3T3 cells were treated
with Hoxa10 siRNA and nonspecific control (NS) for 72 h. The knockdown effect is shown by Western blotting. (B) DNA samples from ChIP with
HOXA10, nonspecific IgG, methylated histone K4 (H3K4), and acetylated histone H4 (ACH4) were amplified by gene-specific (Sp) and 3 control
UTR primers (Table 1) for the indicated gene promoters. The left panel for each gene shows the effect of Hoxa10 siRNA on HOXA10 recruitment
in ChIP assay of the indicated promoter. The right panel shows the status of H3K4 methylation or H4 acetylation of the chromatin modification
by Hoxa10-specific knockdown. (C) ChIP-reChIP assays were performed to identify the association of coregulatory factors p300 and CBP with
HOXA10 on the Runx2 and OC promoters. A HOXA10 ChIP was performed with HOXA10 antibody, and the resulting chromatin immunopre-
cipitate (second input) was subjected to reChIP with the indicated antibodies () (secondary pull-down). Normal IgG and green fluorescent protein
(GFP) antibodies provided controls. The DNA fragments for Runx2 and OC were amplified as described in Materials and Methods. (D) Schematic
illustration to show how HOXA10 belongs to an epigenetic coregulatory complex for remodeling chromatin to induce transcription of osteogenic
genes. We propose that HOXA10 may be among the earliest factors recruited to bone promoters. HOXA10 recruitment is followed by the
coordinated occupancy of other bone-related transcription factors for maximal expression of individual genes during stages of differentiation. HD,
homeodomain.
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ment (87). The TTAT regulatory element is recognized by
several HOX proteins; however, protein-DNA interactions as
well as protein-protein interactions are dependent on the con-
textual sequence of the core TTAT motif (8, 13, 57). Our
analysis of the functional specificity of the Runx2 Hoxa10 site 1
and no other core motifs in the 0.6-kb Runx2 promoter is
consistent with other studies evaluating the specificities of
Hoxa10 sites (4, 72, 74). Although several HOX proteins are
likely present in osteoblast nuclear extracts (e.g., HOXA9),
our findings revealed a supershifted/block shifted complex by
the HOXA10 antibody. However, it is possible that other HOX
protein interactions may occur at this and potentially other
HOX motifs within the Runx2 gene. Our data do support the
concept that the Runx2 site 1 (TTAT) has a high degree of
specificity for HOXA10 binding. Interestingly, the OC gene is
characterized by a TTAC core motif, implicating this motif in
the formation of complexes that support a high degree of OC
expression in mature osteoblasts. It is also noteworthy that the
flanking nucleotides are distinct among the four target genes
studied here (Table 2). This finding implies that their se-
quences may hold information for the dynamic association of
HOXA10 with an individual gene throughout differentiation.
HOXA10 is expressed in many different tissues in which its
functions have been addressed and may be related to its activities
in bone tissue. Progesterone and 17-estradiol, hormones that
regulate turnover of adult bone (53, 63), increase Hoxa10 expres-
sion (16, 48). HOXA10 regulates hematopoietic differentiation in
part via activation of p21 (WAF1/CIP1), the cyclin-dependent
kinase inhibitor (9, 25). In the spinal cord, expression of Hoxa10
is confined to the postmitotic cell population (15). We find that
HOXA10 is expressed in proliferating cells and upregulated in
postproliferative mature osteoblasts in vitro. HOXA10 is also a
target of induction by vitamin D3 (66), a hormone that increases
the expression of osteoblast-related genes. Thus, HOXA10 ap-
pears to have a broad role in gene regulation for contributing to
cell differentiation. Our studies have added to the growing rec-
ognition that Hox genes have important functions in the adult,
including now the skeleton (55).
In conclusion, our characterization of HOXA10 positive reg-
ulation of genes that represent major functional components
for bone formation, including those encoding RUNX2 (a bone
essential transcription factor), alkaline phosphatase (required
for matrix mineralization), bone sialoprotein (an important
cell matrix-binding phosphoprotein with hydroxyapatite nucle-
ation capabilities), and OC (the calcium binding bone-specific
protein) (47), solidifies the concept that HOXA10 is an im-
portant regulator of gene expression throughout the progres-
sion of bone formation. These novel functions for HOXA10 in
regulating target genes for osteoblast differentiation and bone
formation in the postnatal skeleton have broad implications for
HOXA10 functions in normal bone metabolism and bone-
related disorders.
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